A5071040943- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Gallbladder and Bile Duct Disorders
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Acute Myeloid Leukemia Research
- Gastric Cancer Management and Outcomes
- Cancer Cells and Metastasis
- Nuclear Structure and Function
- Cancer Treatment and Pharmacology
- Genetic factors in colorectal cancer
- Colorectal and Anal Carcinomas
- Palliative Care and End-of-Life Issues
- Peptidase Inhibition and Analysis
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer survivorship and care
- Neuroblastoma Research and Treatments
- Histone Deacetylase Inhibitors Research
- Studies on Chitinases and Chitosanases
- Chronic Myeloid Leukemia Treatments
- Pharmacy and Medical Practices
- Advanced Radiotherapy Techniques
- Frailty in Older Adults
Gentofte Hospital
2018-2024
Herlev Hospital
2022-2024
Copenhagen University Hospital
2022-2024
Society of Paediatric Oncology and Haematology
2020
Hôpital Lyon Sud
2019
University of Copenhagen
2018
Abstract Background Older patients with cancer are at risk of physical decline and impaired quality life during oncological treatment. Exercise training has the potential to reduce these challenges. The study aim was investigate feasibility effect a multimodal exercise intervention in older advanced (stages III/IV). Patients Methods Eighty-four adults (≥65 years) pancreatic, biliary tract, or non-small cell lung who received systemic treatment were randomized 1:1 an group control group....
To evaluate the clinical benefit of nivolumab with or without ipilimumab in combination stereotactic body radiotherapy (SBRT) patients refractory metastatic pancreatic cancer (mPC).Between November 2016 and December 2019, mPC were randomly assigned 1:1 to SBRT 15 Gy nivolumab/ipilimumab stratified by performance status (ClinicalTrials.gov identifier: NCT02866383). The primary end point was rate (CBR), defined as percentage complete partial response (PR) stable disease, according RECIST 1.1....
Background Immune-related adverse events due to immune checkpoint inhibitors (ICIs) are not always effectively treated using glucocorticoids and it may negatively affect the antitumor efficacy of ICIs. Interventional studies alternatives lacking. We examined whether interleukin-6 blockade by tocilizumab reduced ICI-induced colitis arthritis. Patients methods with solid cancer experiencing Common Terminology Criteria for Adverse Events (CTCAE v5.0) grade >1 colitis/diarrhea (n=9),...
Oral drug formulations have several advantages compared to intravenous formulation. Apart from patient convenience and favorable pharmacoeconomics, they offer the possibility of frequent administration at home. In this study, we present a new oral irinotecan formulation designed as an enteric coated immediate release tablet which in pre-clinical studies has shown good exposure with low variability. A phase I, dose escalating study assess safety, tolerability, pharmacokinetics efficacy...
4147 Background: Pancreatic cancer (PC) presents one of the most aggressive malignancies for which currently available treatments are modestly effective. We report findings a randomized phase 2 trial (NCT02767557) to test efficacy gemcitabine/nab-paclitaxel (gem/nab) with or without tocilizumab (toc), as first-line treatment in patients locally advanced metastatic PC. Methods: Prior randomization, safety cohort 6 participants received gem 1000 mg/m2, nab 125 mg/m2 (days 1, 8, and 15 each...
The purpose of this study was to evaluate the clinical benefits nivolumab with/without ipilimumab combined with stereotactic body radiotherapy (SBRT) in patients pretreated metastatic biliary tract cancer (mBTC).
Selinexor is an oral Selective Inhibitor of Nuclear Export compound that specifically blocks Chromosomal Region Maintenance protein 1.To evaluate the safety and tolerability escalating doses selinexor plus 5-fluorouracil, leucovorin oxaliplatin (mFOLFOX6) in metastatic colorectal cancer (mCRC) patients.In this multicenter phase I trial, mCRC patients, eligible for oxaliplatin-based treatment, were enrolled to receive on days 1, 3, 8 mFOLFOX6 every two weeks. Primary endpoint was maximum...
To prevent severe toxicity and hospital admissions, adequate management recall of information about side effects are crucial health literacy plays an important role. If age-related factors impact given handling effects, revised ways to give required.We undertook a questionnaire-based survey among 188 newly diagnosed patients with pancreatic cancer or colorectal chemo-naive prostate treated adjuvant first-line palliative chemotherapy comprising satisfaction information, potential hypothetical...
Relapse in patients with acute myeloid leukemia (AML) is common and associated a dismal prognosis. Treatment options are limited the understanding of molecular response patterns still challenging. We analyzed clonal 15 relapsed/refractory AML treated selinexor phase II trial (SAIL). DNA was at three time points showed decline mutated alleles FLT3, SF3B1, TP53 under SAIL treatment. Overall survival (OS) similar between declining versus persisting clones. show an interesting long-term course...
Immunotherapy with checkpoint inhibitors (CPIs) has revolutionised cancer treatment but no convincing effect in metastatic castration-resistant prostate (mCRPC). It been suggested that a combination of CPI and hypofractionated stereotactic body radiotherapy (SBRT) may work synergistically, recent trials have supported this. We hypothesise adding SBRT to can improve response rates patients mCRPC. The CheckPRO trial is an open-label, randomised, two-stage, phase II trial. aim enrol randomise...
YKL-40, also known as chitinase-3-like protein 1 (CHI3L1), is a secreted glycoprotein produced by various cell types including stromal, immune, and cancer cells. It contributes to progression through tumor-promoting inflammation has been shown inhibit the cytotoxicity of T NK lymphocytes. In vivo studies have demonstrated synergistic anti-cancer effects blocking YKL-40 in combination with immune checkpoint inhibitors (ICIs). Biomarkers for prediction response ICIs are highly needed. We...
Abstract Introduction: Pancreatic cancer has a poor prognosis especially when identified at advanced stages. Globally in 2020, >450,000 people died from the disease. For those with locally or metastatic cancer, standard of care treatment is chemotherapy. Preliminary studies show that some patients advanced-stage disease respond to immune checkpoint blockade treatment. Determining response therapy using imaging techniques can be challenging. There clinical unmet need for noninvasive...
<div>AbstractPurpose:<p>The purpose of this study was to evaluate the clinical benefits nivolumab with/without ipilimumab combined with stereotactic body radiotherapy (SBRT) in patients pretreated metastatic biliary tract cancer (mBTC).</p>Patients and Methods:<p>The a phase 2 randomized trial Simon’s optimal two-stage design requiring 36 evaluable per group after second stage. Sixty-one were included from September 2018 January 2022 (1:1) receive SBRT (15 Gy × 1 on...
<div>AbstractPurpose:<p>The purpose of this study was to evaluate the clinical benefits nivolumab with/without ipilimumab combined with stereotactic body radiotherapy (SBRT) in patients pretreated metastatic biliary tract cancer (mBTC).</p>Patients and Methods:<p>The a phase 2 randomized trial Simon’s optimal two-stage design requiring 36 evaluable per group after second stage. Sixty-one were included from September 2018 January 2022 (1:1) receive SBRT (15 Gy × 1 on...
<p>Trial protocol</p>
<p>Consort Checklist</p>
<p>Supplementary Figure S1. CheckPAC study design Supplementary S2. Best percentage change in target lesions from baseline evaluable patients S3. Kaplan–Meier plot of PFS and OS SBRT/nivolumab/ipilimumab-group (A, C) SBRT/nivolumab-group (B, D) S4. Responder 1 S5. 2 S6. 3 S7. 4 S8. 5 S9. DOR for the five achieving partial response after SBRT/nivolumab/ipilimumab S10. TMB who achieved clinical benefit (stable disease or response) compared to those with no (PD) S11. Distribution PD-L1...
<p>Trial protocol</p>